Diverging the anthracycline class of anti-cancer drugs for superior survival of acute myeloid leukemia patients

Xiaohang Qiao, Sabina Y. van der Zanden, Xiaoyang Li, Minkang Tan, Yunxiang Zhang, Ji-Ying Song, Merle A. van Gelder, Feija L. Hamoen, Lennert Janssen, Charlotte L. Zuur, Baoxu Pang, Olaf van Tellingen, Junmin Li, Jacques Neefjes
doi: https://doi.org/10.1101/2023.11.23.23298950

Data Availability

All data produced in the present study are available upon reasonable request to the authors and with permission of Ruijin hospital.

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240443

Back to top
Posted November 24, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Diverging the anthracycline class of anti-cancer drugs for superior survival of acute myeloid leukemia patients
Xiaohang Qiao, Sabina Y. van der Zanden, Xiaoyang Li, Minkang Tan, Yunxiang Zhang, Ji-Ying Song, Merle A. van Gelder, Feija L. Hamoen, Lennert Janssen, Charlotte L. Zuur, Baoxu Pang, Olaf van Tellingen, Junmin Li, Jacques Neefjes
medRxiv 2023.11.23.23298950; doi: https://doi.org/10.1101/2023.11.23.23298950
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area